Image: Shutterstock
October 28, 2020 02:00 AM EDTUpdated October 29, 06:00 AM
Coronavirus

Covid-19 roundup: Boehringer pulls a drug out of the pipeline for a PhII Covid-19 tri­al; No­vavax de­lays PhI­II tri­al in US, with PhII da­ta com­ing Fri­day

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

John Carroll

Editor & Founder

With big ques­tions still hang­ing over the fate of the vac­cines and drugs now in late-stage de­vel­op­ment for Covid-19, Boehringer In­gel­heim is pulling one of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times